Roivant Sciences Ltd Stock, NASDAQ:ROIV
11-12 St. James's Square, Suite 1, 3rd Floor, London, Greater London SW1Y 4LB
Number of Employees: 863
Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. Its product portfolio includes Vtama, Batoclimab, Brepocitinib, Namilumab, and RVT-2001, which aims to treat psoriasis, atopic dermatitis, thyroid eye disease, and other illnesses. The company was founded by Vivek Ramaswamy on April 7, 2014 and is headquartered in London, the United Kingdom.